AARD vs MKTX · $284.4M cap vs P/E 13, rev $817.1M
Aardvark Therapeutics, Inc. Common Stock (AARD) versus MarketAxess Holdings Inc (MKTX) — a side-by-side from cached financials, not a winner call.
Aardvark Therapeutics, Inc. Common Stock (AARD) is a biotechnology company listed on US.
MarketAxess Holdings Inc (MKTX) is a capital markets company listed on US.
AARD does not have a complete income-statement cache yet.
Latest reported MKTX revenue for 2024-12-31 was $817.1M. Net income was $274.2M. Revenue was up 8.6% from 2023-12-31 to 2024-12-31. MKTX currently screens at market cap $4.00B and trailing P/E 13.3.
AARD currently screens at market cap $284.4M. MKTX currently screens at market cap $4.00B and trailing P/E 13.3.
Not investment advice. Open the AARD and MKTX stock pages for the full models.
Not investment advice.